

Biotime Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.

BioTime operates in the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it is developing new medical and research products using embryonic stem cell technology. Additional information about Embryome Sciences can be found on the web at www.embryome.com. Hextend®, PentaLyte®, HetaCool®, Embryomics™, ESpy™, and ESpan™, are trademarks of BioTime, Inc.

In 2008, Embryome Sciences exclusively licensed "ACTCellerate™" embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology from Advanced Cell Technology. ACTCellerate™ is a recently discovered technology that allows the rapid isolation of highly purified embryonic progenitor cells. Biotime has also licensed a portfolio of patents and patent applications from Advanced Cell Technology, Inc. relating to induced pluripotent stem cells and "embryonic stem cell differentiation technology." The license is for the commercialization of products in human therapeutic and diagnostic product markets.

Biotime also has a manufacturing and distribution agreement with International Stem Cell Corporation through its wholly owned subsidiary Lifeline Cell Technology. The companies will jointly produce and distribute new standardized human and animal stem cell lines, along with corresponding data and reagents.